# ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer

> **NCT00387608** · PHASE1 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 23 (estimated)

## Conditions studied

- Leukemia
- Lymphoma
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** veliparib
- **OTHER:** pharmacological study
- **PROCEDURE:** biopsy

## Key facts

- **NCT ID:** NCT00387608
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2008-02
- **Final completion:** 2009-04
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2012-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00387608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00387608, "ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00387608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*